TQ-BIRD: a databank linking tumor control, treatment side effects, quality of life, and biomarkers for cancer patients
Tumor Control, Treatment Toxicity, Quality of Life and Bio-Imaging Repository Databank (TQ-BIRD) for Cancer Patients-A Master Protocol for Imaging and Blood Biomarker Group
This project will collect blood, imaging, and tissue samples from adult cancer patients to see if biomarker patterns relate to tumor control, treatment side effects, and quality of life.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | The University of Hong Kong-Shenzhen Hospital Academic / other |
| Locations | 1 site (Shenzhen, Guangdong) |
| Trial ID | NCT05061342 on ClinicalTrials.gov |
What this trial studies
This observational databank prospectively collects clinical data, imaging, blood and other minimally invasive biomarker samples, and residual tumor tissue when available from adults receiving any anticancer therapy at participating centers. Tumor response will be classified by RECIST, quality of life by PROMIS, and immune/inflammatory biomarkers (for example lymphocyte subsets, TGF-beta1, interleukins, and IDO metabolites) will be measured before, during, and after therapy. Collected specimens and linked clinical/imaging data will be stored for hypothesis-driven analyses and for use by junior investigators. The project includes healthy adult controls for baseline comparisons and aims to enable correlations between biomarkers, treatment toxicity, tumor control, survival, and patient-reported outcomes.
Who should consider this trial
Good fit: Adults (≥18) with cancer who are scheduled to receive surgery, systemic therapy, radiotherapy or other anticancer care at the participating centers, as well as healthy adult volunteers without active cancer, are ideal candidates.
Not a fit: Patients under 18, those who cannot complete quality-of-life questionnaires, or people not treated at the participating centers are unlikely to benefit from participating.
Why it matters
Potential benefit: If successful, the databank could help predict who is most likely to respond to specific treatments or suffer severe side effects, enabling more personalized cancer care.
How similar studies have performed: Previous biomarker-outcome studies—especially those focused on immune markers—have shown promising signals, but comprehensive repositories that link imaging, tissue, blood, and patient-reported QoL data remain relatively uncommon.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Cancer Patients * 18 years of age and older. * Scheduled to receive any kind of therapy in our center. * Performance status of ECOG 0, 1, 2, or 3. * Able to understand QoL questionnaire. Normal (non cancer) controls * 18 years of age and older healthy volunteers. * Without a history of cancer except for cured skin cancer, without any active cancer. * ECOG Performance status 0, 1, 2, or 3. Exclusion Criteria: Participants who have supposedly limited ability to complete the survey questionnaires of the present study will be excluded.
Where this trial is running
Shenzhen, Guangdong
- UHongKongShenzhen — Shenzhen, Guangdong, China (Recruiting)
Study contacts
- Principal investigator: Feng-Ming (Spring) KONG, Professor — The University of Hong Kong-Shenzhen Hospital
- Study coordinator: Li YANG, Dr.
- Email: yangl1@hku-szh.org
- Phone: 0755-86913333-2107
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.